Crinetics Pharmaceuticals, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

Checking your notes…

(in thousands, except per share data)

	Three months ended September 30,		Nine months ended September 30,
	2025	2024	2025	2024
Revenues	$143	$—	$1,535	$1,039
Operating expenses:
Research and development	90,464	61,905	247,005	173,590
Selling, general and administrative	52,265	25,892	137,633	71,558
Total operating expenses	142,729	87,797	384,638	245,148
Loss from operations	(142,586)	(87,797)	(383,103)	(244,109)
Other income (expense):
Interest income	12,544	11,006	40,833	27,067
Other expense, net	(49)	(37)	(232)	(301)
Total other income, net	12,495	10,969	40,601	26,766
Loss before equity method investment	(130,091)	(76,828)	(342,502)	(217,343)
Loss on equity method investment	—	—	—	(470)
Net loss	$(130,091)	$(76,828)	$(342,502)	$(217,813)
Net loss per share:
Net loss per share — basic and diluted	$(1.38)	$(0.96)	$(3.66)	$(2.82)
Weighted average shares — basic and diluted	94,215	80,091	93,707	77,173
Other comprehensive income (loss):
Unrealized gain on investment securities	$594	$2,228	$1,280	$1,061
Unrealized loss on foreign currency	(21)	—	(49)	—
Total other comprehensive income	573	2,228	1,231	1,061
Comprehensive loss	$(129,518)	$(74,600)	$(341,271)	$(216,752)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.